Cabozantinib plus nivolumab for kidney cancer with bone spread
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic clear cell kidney cancer (a common type) that has spread to a bone and also to another spot like an organ or soft tissue.
- You have not had cabozantinib (Cometriq) or nivolumab (Opdivo) before.
- You are able to have two biopsies (tissue samples) — one before starting the study drug and one after.
- You have good enough organ function, such as kidneys (GFR at least 30) and liver (blood tests within limits), and a performance status that lets you be up and around (ECOG 0-2).
- You do not have uncontrolled high blood pressure, major heart problems, or active bleeding risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
This trial tests a new oral drug (HC-7366) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced clear cell kidney cancer. The goal is to see if adding this new drug can help shrink tumors or slow the cancer's growth.
This trial looks at how well cabozantinib works in people with advanced kidney cancer that has spread. It focuses on patients who had a quick response or a long response to the drug.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.